BIOCEPT, INC. (NASDAQ:BIOC) Files An 8-K Other Events

BIOCEPT, INC. (NASDAQ:BIOC) Files An 8-K Other Events
Item 8.01Other Events.

Story continues below

On January 30, 2018, Biocept, Inc. (the “Company”) announced the closing of a “best efforts” public offering of 32,854,606 shares of its common stock and warrants to purchase up to an aggregate of 32,854,606 shares of its common stock at a combined offering price of $0.45. The warrants have a per share exercise price of $0.50, are exercisable immediately and will expire five years from the date of issuance. The Company received proceeds from the offering of approximately $13.3 million, after deducting the applicable placement agents’ fee and estimated offering expenses payable by the Company.

The offering was made to the Company’s effective registration statement on Form S-1 (Registration Statement No. 333-221648), which was declared effective by the Securities and Exchange Commission on January 25, 2018. Dawson James Securities, Inc. and WestPark Capital, Inc. acted as placement agents in connection with the offering. Dawson James Securities, Inc. served as sole bookrunner.

The form of the Warrant issued in connection with the offering is filed herewith as Exhibit 4.1.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

4.1Form of Warrant to Purchase Common Stock


BIOCEPT INC Exhibit
EX-4.1 2 bioc-ex41_6.htm EX-4.1 bioc-ex41_6.htm     Exhibit 4.1   SERIES A COMMON STOCK WARRANT CERTIFICATE   BIOCEPT,…
To view the full exhibit click here

About BIOCEPT, INC. (NASDAQ:BIOC)

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

An ad to help with our costs